Background-Cardiac metabolism is critical for the functioning of the heart, and disturbance in this homeostasis is likely to influence cardiac disorders or cardiomyopathy. Our laboratory has previously shown that SNRK (sucrose nonfermenting related kinase) enzyme, which belongs to the AMPK (adenosine monophosphate-activated kinase) family, was essential for cardiac metabolism in mammals. Snrk global homozygous knockout (KO) mice die at postnatal day 0, and conditional deletion of Snrk in cardiomyocytes (Snrk cmcKO) leads to cardiac failure and death by 8 to 10 months. Methods and Results-We performed additional cardiac functional studies using echocardiography and identified further cardiac functional deficits in Snrk cmcKO mice. Nuclear magnetic resonance-based metabolomics analysis identified key metabolic pathway deficits in SNRK knockdown cardiomyocytes in vitro. Specifically, metabolites involved in lipid metabolism and oxidative phosphorylation are altered, and perturbations in these pathways can result in cardiac function deficits and heart failure. A phosphopeptide-based proteomic screen identified ROCK (Rho-associated kinase) as a putative substrate for SNRK, and mass spec-based fragment analysis confirmed key amino acid residues on ROCK that are phosphorylated by SNRK. Western blot analysis on heart lysates from Snrk cmcKO adult mice and SNRK knockdown cardiomyocytes showed increased ROCK activity. In addition, in vivo inhibition of ROCK partially rescued the in vivo Snrk cmcKO cardiac function deficits. Conclusions-Collectively, our data suggest that SNRK in cardiomyocytes is responsible for maintaining cardiac metabolic homeostasis, which is mediated in part by ROCK, and alteration of this homeostasis influences cardiac function in the adult heart. (Circ Cardiovasc Genet. 2016;9:474-486.
C ardiomyopathy is a complex disorder influenced by several factors. Some of these factors include impaired endothelial function and sensitivity to various ligands (β-agonists), altered intracellular calcium homeostasis, and accumulation of connective tissue, such as insoluble collagen. 1 Recently, cardiomyopathy as a consequence of early alterations in cardiac metabolism has been proposed, particularly with respect to diabetes mellitus. 2 A potential link between cardiac metabolism and function is the ROCK (Ras homolog family member A [RhoA]-associated kinase) signaling pathway. The RhoA/ROCK signaling pathway has been implicated in several cardiovascular and metabolic disorders, such as atherosclerosis, cardiac hypertrophy, and diabetes mellitus. 3 
ROCK
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is a serine threonine kinase involved in regulating various cellular processes, such as cell contraction, migration, proliferation, apoptosis/survival, and gene expression/differentiation. 4 Interestingly, pharmacological inhibition of RhoA/ ROCK activity has been shown to improve cardiac function in diabetes mellitus-induced cardiomyopathy. 5 To date, signaling molecules regulating ROCK activity have primarily been restricted to the RhoA pathway. Our laboratory has identified a novel member of the AMPK (adenosine monophosphateactivated kinase) family, namely, SNRK (sucrose nonfermenting-related kinase), that is essential for angiogenesis 6 and responsible for cardiac metabolism in mammals. 7 Here, we implicate SNRK as a putative regulator of ROCK activity in cardiomyocytes.
Cardiomyocyte metabolism is developmentally dynamic, in that the fetal heart primarily uses glucose as its major energy substrate, and during postnatal maturation, the heart switches to primarily using fatty acid oxidation to meet its energy demands. 8, 9 In our previous work, 7 we reported that the global Snrk KO mice die within 24 hours after birth and display enlarged hearts, and lethality is associated with metabolic defects in cardiac tissues. SNRK maintains metabolic homeostasis via regulation of the pACC (phosphorylated acetyl-coA carboxylase)-phosphorylated AMPK (pAMPK) pathway during this transitional period in development. 7 Furthermore, cardiac-specific conditional Snrk KO (Snrk cmcKO) adult mice display severe cardiac functional deficits and lethality within 8 to 10 months. We extended this work further in this study and identified ROCK as a putative substrate for SNRK that contributes to this metabolic deficit in the heart. Nuclear magnetic resonance (NMR)-based metabolomics in human embryonic stem cell-derived cardiomyocytes and signaling studies in both adult heart lysates and cultured cardiomyocytes collectively imply that SNRKmediated ROCK signaling pathway is an important regulator of cardiac function in mammals.
Methods
Detailed methods are described in the Data Supplement.
Fasudil Rescue
Male and female mice between 6 and 4 months of age were given fasudil (10 mg/kg) or saline daily for 28 days via intraperitoneal injections. Echocardiography analysis was performed immediately before the initial injection, and echocardiography imaging was repeated at 14 and 28 days. At the end of the experiment, the mice were euthanized using CO 2 and cervical dislocation as per the approved Institutional Animal Care and Use Committee animal protocol.
Metabolomics Analysis
Cardiomyocytes treated with either nonsilencing shRNA (short hairpin RNA) control or shSNRK (short hairpin RNA targeting SNRK) lentivirus were cultured in Roswell Park Memorial Institute medium containing B27 (no insulin) for 48 hours before sample collection. Sample collection and extraction was performed as described previously in Bhute and Palecek. 10 1 H NMR spectra were acquired using standard NOESYPR1D pulse sequence (RD-90°-t1-90°-tm-90°acquire) with a relaxation delay of 1 s, a mixing time of 100 ms, and a prescan delay of 30 μs and consisted of 128 transients or free induction decays collected into 48K complex data points with a spectral width of 12 ppm and an acquisition time of 4 s. Free induction decays were zero-filled to 128K data points and multiplied by an exponential window function (line broadening=0.5 Hz). The chemical shifts were referenced to the 3-(trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid or TMSP-d4 peak (δ=0 ppm) using TopSpin software (version 3.1; Bruker). Spectral processing like phasing, baseline correction, and solvent region removal (water and dimethyl sulfoxide) was performed using ACD/1D NMR processing (Advanced Chemistry Development). Targeted profiling 11 was performed using Chenomx NMR Suite Profiler (version 7.7; Chenomx Inc), and the concentrations were references to 3-(trimethylsilyl)-2,2,3,3-tetradeuteropropionic acid or TMSP-d4. Peak annotation was performed based on the existing Chenomx library and the human metabolome database. 12 The metabolite concentrations were exported to an Excel file for further analysis.
The concentration data matrix was normalized by the total concentration of metabolites, which was equivalent to normalization by total spectral area in each sample to evaluate the metabolite fractions and also to account for the differences in cell number and efficiencies of extraction. Statistical and pathway analysis was performed using MetaboAnalyst 3.0. 13 The concentration data were autoscaled (mean centering followed by dividing each variable by the standard deviation) before principal component analysis, and student's t test was performed assuming unequal group variance, and α was chosen to be 0.05. Pathway topology analysis was performed in MetaboAnalyst's pathway analysis module using global test algorithm for pathway enrichment (adjusted for multiple testings) and out-degree centrality to assess importance. The Homo Sapiens library was used for analysis, and the metabolic pathways with an impact score >0 and false discovery rate <0.05 were considered to be significantly enriched.
Protein Kinase Array
Purified SNRK protein was provided to Invitrogen (Life Technologies) for kinase substrate identification service on ProtoArray human protein microarray. In short, SNRK was assayed at concentrations of 5 and 50 nmol/L on ProtoArray human protein microarrays v5.0. All possible kinase substrates at each concentration of SNRK were evaluated by their Z-factor rank within the array and were compared with the negative control assay. A protein was defined as being a candidate substrate if it met the following conditions: the Z-factor, or signal-tonoise ratio, was >0.35 on at least one array, indicating a signal >1.5fold above the noise. The signal-used value was >2000 relative units on at least one array probed with SNRK and was >2-fold higher than the signal-used value for the corresponding protein in the negative control assay. The replicate spot coefficient of variance was <50% on the corresponding array. The interassay coefficient of variance was <50%. Additional experimental details are available on request.
In Vitro ROCK Phosphorylation Protocol
Human umbilical vein endothelial cells (Lonza CC2519) were lysed with radioimmunoprecipitation assay buffer (Sigma) containing complete mini EDTA-free protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor (Roche). Samples were incubated on ice for 20 minutes and cleared at 13 300 rpm at 4°C for 30 minutes. ROCK1 was immunoprecipitated using an anti-ROCK1 antibody (Cell Signaling Technology) with protein G agarose beads (Thermo Scientific). Immunoprecipitates were washed 3× with dilution buffer (10 mmol/L Tris, 130 mmol/L NaCl, 0.05% Triton-X-100, 0.1% BSA, protease inhibitors). Additional washes with 50 mmol/L Tris (pH 8.0) and Tris-Saline (10 mmol/L Tris HCl, 140 mmol/L NaCl; pH 8.0) were also performed. The Lowry quantification method was used to determine the protein concentration. Immunoprecipitated ROCK1 protein was incubated with or without 5 to 30 nmol/L purified SNRK protein in the presence of 3 μmol/L γ-ATP-32 (Perkin Elmer) and 1 μmol/L ATP (Cell Biolabs) in kinase buffer (20 mmol/L HEPES [pH 7.7], 20 mmol/L MgCl 2 , 2 mmol/L DTT, 1× protease inhibitor [Roche] and 1× phosphatase inhibitor [Roche]). The samples were allowed to incubate for 15 minutes at 30°C. After incubation, the samples were washed 2 to 3 times with kinase buffer and resuspended in Lamelli sample buffer. Five microliter of the reaction was reserved for radioactive analysis, and the remaining samples were resolved on a 10% Mini-PROTEAN TGX precast gel (BioRad) and subjected to SDS-PAGE. The gel was then dried and exposed to autoradiography film.
Western Blot Analysis
Adult heart tissues were collected immediately after euthanization, and the proteins were isolated using homogenization in radioimmunoprecipitation assay buffer (Sigma) with complete mini ETDA-free protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor (Roche) using a Qiagen TissueRuptor. Methodologies related to protein estimation and quantification were described previously. 7 The following antibodies were used: anti-myosin-binding subunit (MBS; BioLegend), anti-phospho MBS (pMBS; Cell Signaling December 2016 Technology/MBL International); anti-ROCK1 (BD Bioscience); anti-ROCK2 (BD Bioscience); anti-extracellular signal-regulated kinase (ERK; Cell Signaling Technology); anti-phospho ERK (pERK; Cell Signaling Technology); anti-protein kinase B (AKT; Cell Signaling Technology); anti-phospho AKT (pAKT; Cell Signaling Technology); anti-inhibitor of kappa B kinase (IKK; Cell Signaling Technology); anti-phospho IKK (pIKK; Cell Signaling Technology); anti-Tubulin (Sigma), anti-rabbit horseradish peroxidase (HRP; Cell Signaling Technology), and anti-mouse HRP (Cell Signaling Technology).
Statistics
Student's unpaired t test was used for comparison analysis for the cardiomyocyte western blot, metabolomics, and trichrome staining analysis. Mann-Whitney test was used for comparison analysis for the adult heart Western blot analysis and all of the echocardiographic data analysis. The results are described as means (±standard error of the mean). A P value of <0.1 was considered to be approaching significance. A P value of <0.05 was considered significant when comparing 2 parameters. For all of the in vivo and in vitro ROCK signaling and inhibitor experiments, a P value of <0.05 was considered to be slightly significant, and a P value of <0.0125 was considered significant because of P value correction for multiple comparisons. Sample data values for the trichrome staining analysis and the Western blot experiments are provided in Table I in the Data Supplement. Sample data values for the metabolomics data are provided in Table II in the Data Supplement.
Results
Snrk Cardiac (cmcKO) Conditional Knockout Adult Mice Show Myocardial Dysfunction and Increased Cardiac Fibrosis
Previously, our laboratory assessed the role of Snrk in mammalian development and concluded that SNRK is essential for cardiac metabolism. 7 In that study, we generated and validated the global and cardiac-specific (MYH6CRE) 14 conditional Snrk cmcKO mouse reagents. 7 Homozygous loss of Snrk (LoxP/LoxP) in cardiomyocytes results in lethality between 8 and 10 months of age, and heterozygous loss of Snrk (LoxP/ WT) showed lethality shortly after 1 year of age. Echocardiography analysis on 6-month-old adult male mice showed significant enlargement of the left ventricle internal diameter in systole and diastole, significant increase in end-diastolic volume and end-systolic volume, and significant decrease in the ejection fraction (EF) and the fractional shortening (FS) in the Snrk cmcKO (MYH6CRE Snrk LoxP/LoxP ) mice compared with the CRE-negative littermates. 7 We now performed strain and strain rate imaging analysis ( Figure 1A ), which showed that Snrk cmcKO mice display significantly worsening strain patterns, including decreased radial strain (P=0.0286), increased circumferential strain (P=0.0286), and decreased strain rates S (P=0.0286). The strain rate changes correlate with a decrease in systolic function. The Snrk cmcKO mice also display an increased strain rate E (P=0.0286) that is associated with worsening diastolic function. Furthermore, the pulmonary acceleration time (P=0.0571), ejection time (P=0.0571; Figure 1B ), and right ventricular outflow tract time-velocity integrals (TVI) were also decreased in Snrk cmcKO mice (P=0.0571; Figure 1C ). All together, these findings are consistent with those of a dilated cardiomyopathy, with a resultant increase in pulmonary artery pressure.
We next investigated whether myocardial stiffening and impaired cardiac function could be the result of increased extracellular matrix deposition, a phenomenon described as myocardial fibrosis. 15 We performed trichrome staining on Snrk cmcKO heart tissue sections ( Figure 1D ). Snrk cmcKO showed a significant increase in fibrosis staining (CREnegative 10.38%, cmcKO 19.32%; P=0.0212; Figure 1E ; Table I in the Data Supplement). These data indicate deformation in the heart segments, resulting in altered myocardial function and suggest that Snrk in cardiomyocytes is critical for maintaining heart contractility.
SNRK Knockdown Cardiomyocytes In Vitro Show Defective Metabolism
To investigate what might be amiss in cardiomyocytes in the absence of SNRK, we investigated changes in metabolism in SNRK knockdown cardiomyocytes in vitro because previous data on Snrk cmcKO mice showed cardiac metabolic defects. 7 Cardiomyocytes treated with either nonsilencing short hairpin RNA control or efficacy-confirmed shSNRK lentivirus were subjected to NMR-based metabolomics measurement as described in the Methods section. The heat maps ( Figure 2A Among the increased metabolites, we observed significant increase in multiple osmolytes, including glycerophosphocholine (fold change, 1.44; P=0.0046) and taurine (fold change, 1.27; P=0.038). We also observed an increase in a few essential amino acids, including valine and threonine, while majority of the nonessential amino acids, including alanine (P<0.1), asparagine, aspartate, glutamate, and glutamine, showed a significant decrease because of SNRK knockdown (P<0.05). This indicates significant changes in amino acid-related metabolic pathways, which is also observed in pathways analysis ( Figure 2C ). Interestingly, glycerol was significantly increased because of SNRK knockdown relative to control (fold change, 1.38; P=0.018). Glycerol can serve as a substrate for energy in cardiomyocyte, 16 and we observe several other metabolites associated with energy metabolism, including citrate, fumarate, malate, succinate (P<0.05), pyruvate, and nicotinamide adenine dinucleotide (P<0.1), to be significantly reduced because of SNRK knockdown in cardiomyocytes. This indicates that SNRK can play a crucial role in energy homeostasis in cardiomyocytes.
Further pathway topology analysis ( Figure 2C ) and metabolite set enrichment analysis ( Figure 2D ) suggested significant changes in alanine, aspartate, and glutamate metabolism (P=0.002; Figure 2C ; Figure II in the Data Supplement), citrate cycle (P=3.47E-06; Figure 2C ; Figure III in the Data Supplement), taurine and hypotaurine metabolism (P=0.002), aminoacyl t-RNA biosynthesis (P=0.009), and glycine, serine, and threonine metabolism (P=0.01; Figure 2C ). Specific metabolites and amounts that changed in SNRK knockdown cardiomyocytes are indicated in Tables II and III in the Data Supplement. Taking the in vivo and in vitro data together, SNRK in cardiomyocytes plays an instrumental role in maintaining metabolic homeostasis, which is critical for the normal functioning of the heart.
ROCK Is a Putative Substrate of SNRK
To identify signaling proteins responsible for the cardiac function deficits observed in Snrk cmcKO mice in vivo, we performed a phosphopeptide proteomic screening using pure SNRK protein generated in the laboratory. Human histidinetagged SNRK protein was generated in bacteria ( Figure outsourced the kinase profiling to Life Technologies. An in vitro protein kinase experiment was performed on 9000 N-terminal Glutathione S-transferase fusion proteins on an array at 2 SNRK protein concentrations (5 and 50 nmol/L). This screen identified ROCK1 as one of the top hits along with several members of the transforming growth factor-β signaling pathway (Activin A receptor type 1 also known as ALK2, Activin A receptor like type 1 also known as ALK1, Mothers against decapentaplegic homolog 3, Bone morphogenetic protein receptor type 2) that showed 2-fold or more phosphorylation compared with the negative control (Table IV in the Data Supplement). We confirmed the ROCK1 phosphorylation in vitro using a ROCK kinase assay ( Figure 3A ). ROCK1 protein was immunoprecipitated from human umbilical vein endothelial cells ( Figure 3A , immunoprecipitation blot) and was incubated with purified SNRK protein in the presence of radiolabeled phosphate (P 32 ). As shown ( Figure 3A , lane 2), a P 32 -labeled band is observed in the lane with immunoprecipitated ROCK plus SNRK protein at the correct size for the ROCK1 protein, which was quantified in 3 independent experiments ( Figure 3A, quantification panel) . In addition, we performed multistage fragmentation tandem mass spectrometry on ROCK1 immunoprecipitated from human umbilical vein endothelial cells in the presence or absence of SNRK. The ROCK1 band was excised and subjected to in-gel tryptic digestion. The resulting peptides were analyzed by multistage fragmentation mass spectral analysis. 17 The data for ROCK1 identified residues S27, T237, and S479 ( Figure V in the Data Supplement, blue circles) that resides in the N-terminal region. These sites are distinct from those reported in the literature ( Figure V in the Data Supplement, magenta circles) or previously identified using proteomic approaches ( Figure  V in the Data Supplement, yellow highlighted residues). Collectively, these data suggest that ROCK1 is a direct target of SNRK, and phosphorylation of ROCK by SNRK at specific residues is likely to influence its downstream activity.
We next evaluated ROCK activity by determining the amount of phospho-Threonine 853 in the pMBS of myosin light chain phosphatase, a key enzyme in the RhoA-ROCK muscle contraction signaling cycle. We performed Western blots for ROCK1, ROCK2, and pMBS protein levels in Snrk cmcKO adult ( Figure 3B ) heart lysates. Of the proteins investigated, pMBS levels were higher in adult Snrk cmcKO hearts (MYH6CRE SNRK L/L; Figure 3B ; P=0.1) compared with CRE-negative controls. We also investigated SNRK knockdown cardiomyocytes in vitro for pMBS and observed an increase that was not significant ( Figure 4A; P=0.36, n=3) . Interestingly, when control and shSNRK knockdown cardiomyocytes were treated with the ROCK inhibitor Y27632 ( Figure 4A ), there was a slightly significant decrease in pMBS levels compared with those in the control-treated shSNRK knockdown cardiomyocytes (40.75%; P=0.041, n=3). Specific sample data values are indicated in Table I in the Data Supplement. Collectively, the phosphoproteomic analysis and signaling data suggest that ROCK is a substrate of SNRK, and ROCK activity is attenuated by SNRK in vivo and in vitro in cardiomyocytes.
SNRK-ROCK Signaling in Cardiomyocytes
We next investigated signaling pathways that can be regulated by ROCK signaling, such as AKT and mitogen-activated protein kinase (ERK) in both in vivo Snrk cmcKO mice ( Figure 3B ) and in vitro SNRK knockdown cardiomyocytes ( Figure 4B-4D ). ROCK is known to regulate the PI3K (phosphoinositide 3-kinase)-AKT pathway by activating the phosphatidylinositol (3,4,5)-trisphosphate phosphatase called phosphatase and tensin homolog, which results in a reduction in pAKT levels. 18, 19 In addition, ROCK has also been shown to influence ERK signaling in smooth muscle cells. 20 Western blot analysis was conducted on Snrk WT (CRE Negative) and Snrk cmcKO (MYH6CRE SNRK L/L) heart lysates, as well as on control and shSNRK knockdown cells, with and without the ROCK inhibitor Y27632. Loss of SNRK in the heart resulted in decreased pAKT ( Figure 3B ; 46.15%, P=0.1, n=3) and the AKT downstream effector pIKK ( Figure 3B;  44.62%, P=0.1, n=3) , which suggests decreased AKT signaling in the Snrk cmcKO hearts. We also observed a trend toward increased pERK ( Figure 3B; 183.47%, P=0.2, n=3) in the heart lysates. Specific sample data values are indicated in Table I in the Data Supplement. Surprisingly, knockdown of SNRK in cardiomyocytes resulted in a nonsignificant change in pAKT ( Figure 4B ; 171.07%, P=0.136, n=4) and pERK ( Figure 4D ; 311.64%, P=0.212) and a significant increase in pIKK ( Figure 4C ; 254.38%, P=0.012, n=3). Inhibition of ROCK signaling using the ROCK inhibitor Y27632 was able to significantly decrease the pMBS levels in the shSNRK cardiomyocytes compared with the control-treated shSNRK cardiomyocytes ( Figure 4A ; control 123.35%, shSNRK 40.75%; P=0.041, n=3). pAKT, pERK, and pIKK levels did not significantly change in the presence of the ROCK inhibitor ( Figure 4C ), suggesting that ROCK signaling is not the only molecule involved in regulating pAKT, pERK, and pIKK signaling in cultured cardiomyocytes. These results collectively suggest that SNRK directly influences ROCK signaling in cardiomyocytes in vivo and in vitro.
SNRK-ROCK Signaling Is Required for Normal Cardiac Function
Altered ROCK signaling has been previously implicated in cardiac hypertrophy and ventricular remodeling. 4, 21, 22 To determine whether the cardiac defects observed in the Snrk WT (CRE Negative) and Snrk cmcKO (MYH6CRE SNRK L/L) mice are attributed to increased ROCK activation, Snrk WT (CRE Negative) and Snrk cmcKO (MYH6CRE SNRK L/L) mice were treated with the ROCK inhibitor fasudil. 23 To assess changes in cardiac function, echocardiography was conducted before drug treatment and after 4 weeks of daily fasudil or saline injection ( Figure 5 ; Table V in the Data Supplement). Fasudil treatment in Snrk cmcKO mice resulted in stabilization of EF and FS phenotypes, from 55.55% (cKO-fasudil) to 50.66% (cKO-saline) EF and from 24.77% to 22.7% FS before treatment to 53% EF and 23.23% FS after fasudil treatment compared with the salinetreated Snrk cmcKO mice, which displayed continued declines in EF (44.55%; P=0.0286) and FS (18.9%; P=0.0286). Enddiastolic volume did not show a significant change in the Snrk cmcKO mice (0.0064) treated with fasudil compared with baseline (0.0070; P=0.6905), whereas end-diastolic volume continued to increase in the saline-treated Snrk cmcKO mice from 0.0066 at baseline to 0.0082 at 4 week (P=0.0286). End-systolic volume did not increase in the fasudil-treated Snrk cmcKO mice but did increase in the saline-treated mice (baseline 0.0029-4 weeks, 0.0046; P=0.0286), indicating a preserved EF in the fasudil-treated mice. IVRT showed a similar trend, with a slight decrease in the fasudil-treated Snrk cmcKO mice (14.45 at baseline to 12.41 at 4 weeks; P=0.3413) and an increase in Snrk cmcKO saline-treated mice (12.4 at baseline to 13.22 at 4 weeks; P=0.0286). These data indicate that increased ROCK activity is involved in generating the cardiac functional deficits observed in the Snrk cmcKO mice and that inhibition of ROCK results in cardiac functional improvements.
Discussion
In this study, we have identified that a member of the AMPK family, namely SNRK, influences ROCK signaling to maintain cardiac function in the adult. Snrk was first identified in 3T3-L1-differentiated adipocyte cells 24 and compared with Ampkα1 and Ampkα2; Snrk expression in white adipose tissue, brown adipose tissue, heart, and brain is significantly higher. 25 The expression profile of SNRK and the family that it belongs to suggests a role for this enzyme during high metabolic needs like the heart contraction and relaxation cycles. Indeed, in our previous report, 7 we identified that SNRK is a critical regulator of metabolic function during embryonic cardiovascular development and identified the metabolic pAMPK-pACC signaling pathway deregulation in the heart. These results directly support current NMR-based metabolomic analysis data in SNRK knockdown cardiomyocytes, which shows decreased metabolites, such as those involved in alanine, aspartate, and glutamate metabolism ( Figure II in the Data Supplement), as well as citric acid cycle metabolism ( Figure III in the Data Supplement), and increases in metabolites involved in lipid synthesis, such as glycerol ( Figure I in the Data Supplement), 26 which are processes directly influenced by pAMPK-pACC signaling. 27, 28 Interestingly, perturbations in cardiac metabolic output have been observed in patients with heart failure. 29, 30 In normal hearts, the primary metabolic energy source is derived by lipid metabolism/fatty acid oxidation, and in failing hearts, the metabolic substrate changes to glucose metabolism. 31 Furthermore, accumulation of lipids (free fatty acids) in the failing heart can create additional metabolic stress by increasing energy uncoupling and proton leakage and decreasing energy production. 32, 33 In the SNRK knockdown cardiomyocytes, we did not observe any significant changes in glycolysis or glucose metabolism, but we did observe significant alterations in oxidative phosphorylation and lipid metabolism, indicating an important role for SNRK in cardiac metabolism, and loss of SNRK can result in phenotypes similar to those observed during cardiac failure. In addition, taurine and hypotaurine metabolism was found to be increased in the Snrk knockdown cardiomyocytes, indicating the activation of compensatory mechanisms to increased osmotic stress, 34, 35 and further supporting the notion that SNRK is an important regulator of cardiac cellular homeostasis.
To assess the contribution of SNRK to cardiac function, we conditionally deleted Snrk in cardiomyocytes in vivo using MYH6CRE 14 mouse line. The Snrk cmcKO mice develop cardiomyopathy and die at 8 to 10 months of age. 7 The 6-month echocardiographic studies showed changes in left ventricular dimensions and decreased ventricular function consistent with a dilated cardiomyopathy. Left heart failure often result in increased pulmonary artery pressures, and our echocardiography-Doppler interrogation of right heart hemodynamics corroborate this relationship. These mice over time progressively show increased fibrosis and cardiac stiffening, phenotypes associated with dysregulated ROCK signaling. 36, 37 Indeed, we identified 2 key molecules, namely the transforming growth factor-β signaling pathway and ROCK signaling pathways, in our SNRK substrate screen, both of which have been implicated in cardiac stiffening and fibrosis. 37 We posit that SNRK's involvement in the 2 signaling pathways may not be mutually exclusive because both have been implicated in cardiomyocytes function previously. For example, transforming growth factor-β3 and ALK2 regulate ROCK1 expression during valvuloseptal endocardial cushion formation 38 and upregulation of bone morphogenetic protein-2 and antagonized transforming growth factor-β1/ROCK-enhanced cardiac fibrotic signal through activation of Smurf1/Smad6 complex. 37 In this study, we only focused on ROCK because of the overwhelming evidence, suggesting ROCK as a cardiovascular risk factor 39 and its role in cardiovascular physiology and pathophysiology. 4 ROCKs are ubiquitously expressed proteins, and both isoforms ROCK1 and ROCK2 are expressed in the heart. 40 Signaling mechanisms associated with contraction in the vascular smooth muscle cells in the heart are well studied for ROCK. Briefly, intracellular Ca 2+ level increases through activated G-protein-coupled receptors, which in turn stimulate downstream phosphorylation of myosin light chain kinase (activating) and phosphorylation of the MBS (also known as MYPT1) of myosin light chain phosphatase (inactivating). The exchange factor RhoA is the chief upstream activator of ROCK1 to date and has been the established regulator of this pathway 4 ; the net result of which is contraction of smooth muscle cells. Our studies suggest that SNRK is a second player upstream of ROCK, but whether the phosphorylation directly activates or inhibits ROCK activity or whether additional proteins along with SNRK are required for altered ROCK activity is currently unknown. Our data suggest that SNRK is a negative regulator of ROCK signaling, and loss of SNRK increases ROCK activity in cardiomyocytes. Indeed, loss of SNRK in Snrk cmcKO adult (6 months old) mice showed higher levels of pMBS, reinforcing the hypothesis that phosphorylation of ROCK1 by SNRK may be inhibitory (Figure 3 ). The converse experiment would be the overexpression or gain of SNRK in cardiac tissue, which should decrease ROCK activity and consequences associated with it. The resulting phenotype would include improved cardiac function because ROCK1 is necessary for the transition from cardiac hypertrophy to failure. 41 Indeed, 2 abstracts report that SNRK overexpression in the heart improves cardiac metabolic efficiency and response to myocardial ischemia, 42, 43 which support our predictive hypothesis.
We also examined the activation status of additional downstream effectors of ROCK, such as AKT and ERK, and identified altered in vivo expression levels of pAKT and pERK, further suggesting that ROCK activity is altered in vivo when SNRK is absent (Figures 3 and 6 ). Interestingly, we did not see a significant difference in the in vitro expression levels of pAKT, pERK, and pMBS in SNRK knockdown cardiomyocytes. These observations could be attributed to the inherent differences between in vitro culturing conditions and in vivo responses that contain additional non-cardiomyocytes cell types influencing the experimental readout. Additional in vitro studies are necessary to specifically address these differences.
To assess whether attenuation of ROCK signaling in Snrk cmcKO mice is consequential, we treated Snrk cmcKO mice with the ROCK inhibitor fasudil. 23 Before treatment, the Snrk cmcKO mice already displayed cardiac functional defects. After 4 weeks of treatment with the inhibitor, the Snrk cmcKO mice began showing signs of improved cardiac function and stabilization of the phenotype compared with the untreated Snrk cmcKO mice that continued to show decreased cardiac function ( Figure 5 ; Table V in the Data Supplement). These findings suggest that some of the cardiac functional deficits observed in the Snrk cmcKO mice are most likely a result of increased ROCK activity and that SNRK regulation of ROCK signaling is an important component of normal cardiac function.
In summary, our data suggest that an AMPK family member SNRK is a critical metabolic sensor in cardiac tissues and directly influences ROCK signaling in cardiomyocytes, effects that directly contribute to maintaining cardiac metabolic homeostasis and cardiac functional output in mammals. Figure 6 . Proposed model for the mechanism of SNRK regulation of ROCK activity. ROCK is a major downstream effector of the small GTPase RhoA. On activation, ROCK can influence cellular contraction by phosphorylating myosin-binding subunit (MBS, also known as MYPT-1) of the myosin phosphatase complex. Phosphorylation of the myosin phosphatase complex renders the complex inactive, and it is no longer able to remove the active phosphate group from phosphorylated myosin light chain (pMLC). Phosphorylated MLC is active and able to promote cellular contraction. SNRK regulates this process by modulating ROCK activity via phosphorylation of ROCK. ROCK can also influence ERK phosphorylation and nuclear localization, as well as activate PTEN, which in turns inhibits the PI3K pathway, resulting in the inhibition of phospho-AKT. AKT indicates protein kinase B; ERK, extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; PIP3, phosphatidylinositol (3,4,5)-trisphosphate; PTEN, phosphatase and tensin homolog; ROCK, Rho-associated kinase; and SNRK, sucrose nonfermenting related kinase.
